The Hematologic Malignancies Program (HMP) was established in 1995 as the Stem Cell Biology and Therapeutics Program. It was given its present name in 2004 to better reflect the overarching mission of the HMP, i.e. to translate basic scientific discoveries into novel therapeutics for patients with myeloid and lymphoid neoplasms. To support this mission, the HMP has 5 scientific goals. These are to: 1) develop a mechanistic understanding of the role of chromosomal translocations, chromatin remodeling, and transcription factors in regulating normal and malignant hematopoiesis;2) define the receptors and signal transduction pathways employed by malignant hematopoietic cells to respond to specific environmental stimuli;3) investigate the immune response to these cells to develop more effective immune-based therapies;4) create animal models to test promising discoveries coming from the laboratory;and 5) design and conduct innovative, field-leading clinical trials. The Program has been led for the past decade by Alan M. Gewirtz, MD, a pioneer of translational research in the hematologic malignancies. Dr. Edward Stadtmauer, a leader in clinical trials of novel therapeutics for hematologic malignancies and bone marrow transplantation, has served as Co-Leader for the past 2 years. The HMP has 19 primary members, drawn from 5 Departments (Medicine, Pediatrics, Genetics, Pathology, Cancer Cell Biology) within the University of Pennsylvania School of Medicine, who share a strong research interest in the molecular, cellular, structural, biochemical and immunological approaches to understanding blood cancers and their treatment. HMP member interactions are facilitated by common use of Cores, multiple weekly seminars and meetings, collaborative grant submissions, and an annual research retreat. During the last budget period, a total of 38 peer reviewed projects were supported by NCI, NIH, and other non-governmental agencies (LLS, ACS) for a total of $5,693,859 in research funding (annual direct costs) of which $4,927,175 is peer-reviewed and $2,652,239 is from the NCI. During the last review period, HMP members published 333 cancer-related papers. Of these, 13% were intra-programmatic collaborations and 42% resulted from inter-programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593257
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$117,845
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Vachani, Anil; Wong, Yu-Ning; Israelite, Jennifer et al. (2016) Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Med Care :
Ruella, Marco; Barrett, David M; Kenderian, Saad S et al. (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126:3814-3826
Dannoon, Shorouk; Ganguly, Tanushree; Cahaya, Hendry et al. (2016) Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem 59:5684-94
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Karunamuni, Roshan; Naha, Pratap C; Lau, Kristen C et al. (2016) Development of silica-encapsulated silver nanoparticles as contrast agents intended for dual-energy mammography. Eur Radiol 26:3301-9
Bartlett, Edmund K; Peters, Madalyn G; Blair, Anne et al. (2016) Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Ann Surg Oncol 23:250-6
Walsh, Michael F; Nathanson, Katherine L; Couch, Fergus J et al. (2016) Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 882:1-32
Heneghan, Mallorie B; Rheingold, Susan R; Li, Yimei et al. (2016) Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16:223-229.e2
Clark, A S; DeMichele, A; Mankoff, D (2016) HER2 imaging in the ZEPHIR study. Ann Oncol 27:555-7
Strasser, Andrew A; Souprountchouk, Valentina; Kaufmann, Amanda et al. (2016) Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. Tob Regul Sci 2:352-362

Showing the most recent 10 out of 848 publications